Clinical Trials Logo

Migraine clinical trials

View clinical trials related to Migraine.

Filter by:

NCT ID: NCT00742209 Completed - Migraine Clinical Trials

Prevention Study in Adult Patients Suffering From Migraine Headaches

Start date: August 2008
Phase: Phase 2
Study type: Interventional

Purpose of the study is to evaluate dose response relationship, efficacy, safety and tolerability of target doses of GSK1838262 compared to placebo in the prophylactic treatment of migraine headache. Once subjects complete the baseline and meet the randomization criteria, they will complete a 5-wk flexible titration period and then enter the 12 week maintenance period.

NCT ID: NCT00725140 Completed - Migraine Clinical Trials

Standardized sTudy With Almotriptan in eaRly Treatment of Migraine

START
Start date: June 2008
Phase: N/A
Study type: Observational

This is a observational, open, prospective, single arm cohort study within authorized SPC conditions to describe the effectiveness of Almotriptan in treating acute migraine attacks when pain is mild and in the first hour of pain in everyday primary care clinical practice.

NCT ID: NCT00712725 Completed - Migraine Clinical Trials

MK3207 for Treatment of Acute Migraines (3207-005)

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.

NCT ID: NCT00690716 Completed - Migraine Clinical Trials

The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines

Start date: August 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effect of nasal carbon dioxide in the treatment of mild headaches in people who have migraines.

NCT ID: NCT00682734 Completed - Migraine Clinical Trials

Metoclopramide for Migraine: A Dose Finding Study

MDFS
Start date: April 2008
Phase: Phase 3
Study type: Interventional

Metoclopramide is an effective intravenous treatment for acute migraine attacks, but we do not know the best dose to administer. This study compares three different doses of metoclorpamide.

NCT ID: NCT00680823 Completed - Migraine Clinical Trials

Study of Intramuscular Ropivacaine Injections for Treatment of Pediatric Headache

Start date: January 2009
Phase: N/A
Study type: Interventional

Objective: To determine if lower paracervical intramuscular ropivacaine injection is an effective treatment for pediatric headache in an emergency department setting.

NCT ID: NCT00637286 Completed - Migraine Clinical Trials

ZAP, US. Zomig for Appropriate for Primary Care

Start date: July 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine how useful and effective the use of ZOMIG-ZMTā„¢ (zolmitriptan) 5.0 mg and ZOMIG® Nasal Spray (zolmitriptan) 5.0 mg is for patients, in treating migraine over a period of 6 months

NCT ID: NCT00634985 Completed - Migraine Clinical Trials

Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs

Start date: November 2002
Phase: Phase 4
Study type: Interventional

To assess the safety and efficacy of eletriptan for the treatment of migraine in subjects who had not been adequately treated with non-steroidal antiinflammatory drugs (NSAIDs)

NCT ID: NCT00632385 Completed - Migraine Clinical Trials

Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy

Start date: January 2003
Phase: Phase 4
Study type: Interventional

To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy

NCT ID: NCT00617747 Completed - Migraine Clinical Trials

Efficacy and Tolerability of Zolmitriptan Nasal Spray

Start date: September 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and tolerability (the ability not to experience ill effects from the study drug) of a zolmitriptan nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches for up to 12 weeks in adult subjects with migraine headaches